Author + information
- Received April 12, 2019
- Revision received September 9, 2019
- Accepted September 23, 2019
- Published online January 6, 2020.
- Yoshinobu Onuma, MD, PhDa,b,
- Yasuhiro Honda, MDc,
- Taku Asano, MDb,d,
- Hiroki Shiomi, MD, PhDe,
- Ken Kozuma, MD, PhDf,
- Yukio Ozaki, MD, PhDg,
- Atsuo Namiki, MD, PhDh,
- Satoshi Yasuda, MDi,
- Takafumi Ueno, MD, PhDj,
- Kenji Ando, MDk,
- Jungo Furuya, MDl,
- Keiichi Igarashi Hanaoka, MD, PhDl,
- Kengo Tanabe, MD, PhDm,
- Kozo Okada, MD, PhDc,
- Hideki Kitahara, MD, PhDc,
- Masafumi Ono, MDb,d,
- Hajime Kusano, PhDn,
- Richard Rapoza, PhDn,
- Charles Simonton, MDn,
- Jeffrey J. Popma, MDo,
- Gregg W. Stone, MDp,
- Peter J. Fitzgerald, MD, PhDc,
- Patrick W. Serruys, MD, PhDq and
- Takeshi Kimura, MD, PhDe,∗ ()
- aThoraxcenter, Erasmus MC, Rotterdam, the Netherlands
- bCardialysis, Rotterdam, the Netherlands
- cStanford Cardiovascular Institute, Stanford, California
- dAcademic Medical Center, Amsterdam, the Netherlands
- eKyoto University Hospital, Kyoto, Japan
- fTeikyo University Hospital, Tokyo, Japan
- gFujita Health University Hospital, Toyoake, Japan
- hKanto Rosai Hospital, Kawasaki, Japan
- iNational Cerebral and Cardiovascular Center, Osaka, Japan
- jKurume University School of Medicine, Kurume, Japan
- kDivision of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan
- lHanaoka Seishu Memorial Cardiovascular Clinic, Hokkaido, Japan
- mMitsui Memorial Hospital, Tokyo, Japan
- nAbbott Vascular, Santa Clara, California
- oBeth Israel Deaconess Medical Center, Boston, Massachusetts
- pColumbia University Medical Center, NewYork-Presbyterian Hospital, and the Cardiovascular Research Foundation, New York, New York
- qInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom
- ↵∗Address for correspondence:
Dr. Takeshi Kimura, Department of Cardiovascular Medicine, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto 606-8507, Japan.
Objectives The aim of this study was to investigate the vascular responses and fates of the scaffold after bioresorbable vascular scaffold (BVS) implantation using multimodality imaging.
Background Serial comprehensive image assessments after BVS implantation in the context of a randomized trial have not yet been reported.
Methods In the ABSORB Japan trial, 400 patients were randomized to a BVS (n = 266) or a cobalt-chromium everolimus-eluting stent (n = 134). Through 3 years, patients underwent serial angiography and intravascular ultrasound or optical coherence tomography (OCT).
Results Luminal dimension at 3 years was consistently smaller with the BVS than with the cobalt-chromium everolimus-eluting stent (mean angiographic minimal luminal diameter 2.04 ± 0.63 mm vs. 2.40 ± 0.56 mm, mean difference −0.37 mm [95% confidence interval: −0.50 to −0.24 mm]; p < 0.001), mainly because of smaller device area (6.13 ± 2.03 mm2 vs. 7.15 ± 2.16 mm2, mean difference −1.04 mm2 [95% confidence interval: −1.66 to −0.42 mm2]; p < 0.001), and larger neointimal area (2.10 ± 0.61 mm2 vs. 1.86 ± 0.64 mm2, mean difference 0.24 mm2 [95% confidence interval: 0.06 to 0.43 mm2]; p = 0.01) by OCT. BVS-treated vessels did not show previously reported favorable vessel responses, such as positive vessel remodeling, late luminal enlargement, and restoration of vasomotion, although the OCT-based healing score was on average zero (interquartile range: 0.00 to 0.00). At 3 years, intraluminal scaffold dismantling (ISD) was observed in 14% of BVS. On serial OCT, ISD was observed in 6 lesions at 2 years, where the struts had been fully apposed at post-procedure, while ISD was observed in 12 lesions at 3 years, where 8 lesions were free from ISD on 2-year OCT. In 5 cases of very late scaffold thrombosis, strut discontinuities were detected in all 4 cases with available OCT immediately before reintervention.
Conclusions In this multimodality serial imaging study, luminal dimension at 3 years was smaller with the BVS than with the cobalt-chromium everolimus-eluting stent. ISD, suspected to be one of the mechanisms of very late BVS thrombosis, was observed in a substantial proportion of cases at 3 years, which developed between post-procedure and 2 years and even beyond 2 years. (AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 [Absorb™ BVS] in Japanese Population [ABSORB JAPAN]; NCT01844284)
The sponsor (Abbott Vascular) was involved in study design, data collection, data analysis, data interpretation, and writing of this report. The corresponding author had full access to the analyzed data in the study and accepts full responsibility for the integrity of the study and the decision to submit for publication. Drs. Onuma and Serruys are members of the advisory board of Abbott Vascular. Dr. Stone is chairman of the advisory board of Abbott Vascular; and is a consultant to Reva. Dr. Popma has received grants and personal fees from Abbott Vascular. Drs. Namiki, Ueno, Ando, Igarashi, Kozuma, Tanabe, and Kimura have received personal fees for advisory agreements with Abbott Vascular Japan. Drs. Kusano, Rapoza, and Simonton are employees of Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 12, 2019.
- Revision received September 9, 2019.
- Accepted September 23, 2019.
- 2020 The Authors